Region: Ecuador

SENADI considered that there was a likelihood of confusion or association between the mark CHOLOFLIX and Netflix Inc’s earlier mark NETFLIX, which both covered Class 41 services.

11 August 2022

SENADI has found that there was a risk of confusion between the mark BIOVET and the earlier mark BIOVET (and design) for goods in Class 5, even among consumers who are specialised in these types of products.

05 May 2022

The case created controversy when it emerged that the agent who had filed the mark at issue was the SENADI director who decided on the matter.

10 February 2022

A reform of Ecuador’s IP laws came into force on 27 August 2021, providing greater efficiency in prosecuting IP crimes and correcting previous flaws in the border measure system.

05 October 2021

Third-party appropriation of internationally famous trademarks is a problematic phenomenon in Ecuador. Some clarification by the Court of Justice of the Andean Community would arguably be welcome. 

14 July 2021

Featured in IP office tools and services

In exclusive insights, the general director of the Ecuadorian Institute of Intellectual Property (SENADI) reveals the innovative non-core tools and services the registry offers for trademark users – and some of those planned for the future.

03 May 2021

The National Service of Intellectual Rights of Ecuador has recently issued several resolutions which have radically changed the criteria for using invoices as proof of use.

15 January 2021

This case, which saw Discovery Communications LLC prevail on appeal, confirms that the fact that two marks fall within different classes does not necessarily imply an absence of confusion or association among consumers.

30 September 2020

Protecting brands against parasitic trademarks can raise numerous challenges in Bolivia, Colombia, Ecuador and Peru – but there are ways to overcome them.

08 July 2020

Six persons involved in the counterfeiting of pharmaceuticals have been handed prison sentences in Ecuador. Multinational pharmaceutical corporation Pfizer intervened in this case.

28 April 2020